Wall St. falls as Apple drags tech shares lower

Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701

Credit Suisse lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $24.00 (from $38.00) while maintaining a Outperform rating, following the release of a CRL for a competing biosimilar.

Analyst Alethia Young notes the Neulasta biosimilar CRL implies a greater risk for the company to... More

General Electric (GE) Name Russell Stokes as President & CEO of GE Power

GE (NYSE: GE) announced today that Russell Stokes, current president and CEO of GE Energy Connections, has been named president and CEO of GE Power, effective July 3, 2017. He succeeds Steve Bolze, the former president and CEO of GE Power, who has announced his decision to retire. In his new role, Mr. Stokes will lead the integration of the legacy GE Power and Energy Connections businesses into one, power-focused unit called GE Power.

Russell brings a strong combination of operational, industrial and energy experience to this role, and can now scale his... More

General Electric (GE) Announces Additive Manufacturing Partnership with Stryker

GE Additive (NYSE: GE) and Stryker have entered a partnership agreement to support Strykers growth in additive manufacturing. The agreement covers new additive machines, materials and services for Strykers global supply chain operations. The announcement was made at GEs Minds + Machines event, GEs premier industrial internet event dedicated to software, innovation and the sharing of the most powerful digital industrial outcomes.

GE and Stryker share a similar vision and both of us understand the transformative power of... More

Amgen (AMGN) PT Raised to $175 at UBS; Remains Sidelined

UBS raised its price target on Amgen (NASDAQ: AMGN) to $175.00 (from $174.00) while maintaining a Neutral rating. A complete response letter from the FDA denied approval for Coherus' CHS-1701. Also, the Supreme Court ruling on the Sandoz vs. Amgen case appears now to allow companies... More

Amgen (AMGN) PT Raised to $184 at Morgan Stanley; 'Adjusting Model for Biosimilar Neulasta Delay'

Morgan Stanley raised its price target on Amgen (NASDAQ: AMGN) to $184.00 (from $183.00) while maintaining a Overweight rating.

Analyst Matthew Harrison notes positive news for the company, as Neulasta competitor CHS-1701 received a complete response letter and will be delayed by over... More

Apple (AAPL) PT Raised to $170 at Macquarie; 'Bullish on Position in China'

Macquarie raised its price target on Apple (NASDAQ: AAPL) to $170.00 (from $160.00) while maintaining a Outperform rating, following a review of the company's global iPhone outlook.

Analyst Benjamin Schachter suggests a positive outlook on the company heading into the next iPhone cycle, noting strong global... More

Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter

Baird lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $37.00 (from $40.00) while maintaining a Outperform rating. Coherus announced the FDA issued a complete response letter for CHS-1701. The FDA is requesting a subset reanalysis with a revised immunogenicity assay as well as additional... More

Cowen Reiterates Market Perform Rating & $30 PT on General Electric (GE); 'CEO Change Won't Drive Enduring Upward Re-Rating'

Cowen reiterates Market Perform rating and $30 price target on General Electric (NYSE: GE), following the company's announcement of a CEO change.

Analyst Gautam Khanna notes the retirement of former CEO Immelt will result in an up-ward rerating of the shares due to the SOTP... More